Target intelligence / Profile preview

Toll-like receptor 2-Toll-like receptor 6 complex (TLR2/TLR6)

Target
TLR2/TLR6
Molecular classification
Receptor, Other
01

Overview

The Toll-like receptor 2-Toll-like receptor 6 (TLR2/TLR6) complex is a cell-surface pattern recognition receptor (PRR) heterodimer that plays a critical role in the innate immune system. It is primarily expressed on immune cells such as macrophages, monocytes, dendritic cells, and neutrophils, where it recognizes diacylated lipopeptides and other pathogen-associated molecular patterns (PAMPs) from Gram-positive bacteria, mycoplasma, fungi, and viruses. Upon ligand binding, the TLR2/TLR6 complex recruits the adaptor proteins MyD88 and TIRAP/MAL, initiating a signaling cascade that activates the NF-κB and MAPK pathways, leading to the production of pro-inflammatory cytokines and chemokines. In therapeutic development, TLR2/TLR6 agonists like FSL-1, Pam2CSK4, and GSK3277329 are being investigated as vaccine adjuvants, immunotherapies for cancer, and countermeasures for radiation-induced hematopoietic injury. Conversely, TLR2/TLR6 antagonists are being explored to mitigate hyperinflammatory conditions, viral-induced cytokine storms, and autoimmune diseases. However, targeting this complex requires careful management of safety concerns, particularly the risk of inducing systemic inflammatory responses or cytokine release syndrome.

Other names
TLR2/TLR6 heterodimerTLR2-TLR6 heterodimerTLR2:TLR6 complexToll-like receptor 2/6 complexTLR2-TLR6 protein complexToll-like receptor TLR6:TLR2 heterodimeric complex
02

Mechanism of action

Agonist or antagonist of the Toll-like receptor 2/6 complex, modulating downstream MyD88-dependent signaling pathways.

03

Biological functions

Immune responseSignal transductionApoptosisCell proliferationCell death
04

Disease associations

InfectionInflammationCancerNeurodegenerative diseaseOther
05

Safety considerations

Systemic inflammatory response syndrome (SIRS)Cytokine release syndrome (CRS)Autoimmune reactionsHyperinflammation-induced tissue damageSepsis-like symptoms
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Interleukin-6 (IL-6)Interleukin-1 beta (IL-1β)Tumor necrosis factor alpha (TNF-α)Granulocyte colony-stimulating factor (G-CSF)P-selectinHigh mobility group box 1 (HMGB1)S100A8/A9

Beyond the preview

Go deeper on Toll-like receptor 2-Toll-like receptor 6 complex (TLR2/TLR6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toll-like receptor 2-Toll-like receptor 6 complex (TLR2/TLR6).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call